ASSESSMENT OF CARDIOVASCULAR AND RENAL OUTCOMES FOLLOWING DAPAGLIFLOZIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE. A-JMRHS. 2026;4(2):1398-1403. Accessed July 1, 2026. https://ajmrhs.com/journal/article/view/617